PR87085

SAN FRANCISCO, Dec. 8, 2020 /PRNewswire=KYODO JBN/ --

PostEra (https://c212.net/c/link/?t=0&l=en&o=3004173-1&h=522007963&u=https%3A%2F%2Fpostera.ai%2F&a=PostEra ), a biotechnology

company specializing in machine learning solutions for preclinical drug discovery,

today announced a strategic partnership with Pfizer Inc. (NYSE: PFE) with the goal of

accelerating small molecule drug discovery by developing a platform technology based

on generative chemistry.

PostEra's machine learning technology is intended to accelerate the drug

discovery process by designing novel molecular structures with optimised

potency and drug-like properties. PostEra's approaches take chemical synthesis

into account, as well as incorporate design hypotheses of medicinal chemists.

Through the collaboration, the companies will leverage Pfizer's extensive data

and expertise with PostEra's technology capabilities to advance the science of

generative chemistry to produce state-of-the-art, scalable models that could

potentially be deployed across in-house, preclinical drug discovery efforts.

PostEra will receive an upfront payment and is eligible to receive additional

payments as the project progresses. PostEra will also retain ownership rights

to all algorithms developed during the collaboration.

"PostEra is delighted to be working with Pfizer to solve some of the key pain

points in preclinical drug discovery," said Aaron Morris, CEO of PostEra. "As a

team we are proud to be entering this collaboration and will be leveraging

PostEra's many advances in machine learning to help Pfizer accelerate progress

toward novel therapeutics."

"We believe that our investments in machine learning technologies could

potentially help us expedite preclinical drug discovery. PostEra's technology

complements this effort, and we look forward to seeing the results of the

collaboration," said Charlotte Allerton, Head of Medicine Design, Pfizer.

About PostEra

PostEra was founded in 2019 and its technology is built on pioneering academic

research done at the University of Cambridge. The technology addresses some of

the key challenges in drug discovery R&D by integrating molecular design with

chemical synthesis. PostEra partners with drug hunters to help expedite their

preclinical programs while also offering some of its synthesis technology via

its Manifold (https://c212.net/c/link/?t=0&l=en&o=3004173-1&h=2318415732&u=https%3A%2F%2Fpostera.ai%2Fmanifold&a=Manifold )

web platform. PostEra also launched and now helps lead the world's largest

open-science drug discovery effort; COVID Moonshot.

https://postera.ai/

SOURCE  PostEra

CONTACT: Aaron Morris, aaron.morris@postera.ai